Megan Hollasch

Finding effective treatments beyond the first line for patients with locally advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer and an ESR1 mutation remains a challenge following development of resistance to agents.

David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial.

Trastuzumab plus ramucirumab and paclitaxel yielded promising efficacy and a manageable safety profile among patients with previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Zipalertinib demonstrated promising efficacy as well as an acceptable safety profile in heavily pretreated patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions.

Amira Marouf, MD, PhD student, describes the nature of a comparative analysis conducted based on propensity score matching, and discussed the main takeaways regarding the efficacy of PD-1 inhibitors for patients with relapsed/refractory ENKTCL.

Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy followed by adjuvant nivolumab increased pathological complete response rates and prolonged survival compared with neoadjuvant chemotherapy alone in patients with resectable stage IIIA/B non–small cell lung cancer.

Sugemalimab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival vs placebo plus chemotherapy for the first-line treatment of patients with stage IV non–small cell lung cancer irrespective of PD-L1 expression level and tumor pathological type.

Omid Hamid, MD, discusses the key efficacy and safety findings for the combination of fianlimab plus cemiplimab in patients with advanced melanoma.

Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert and dives into the unique mechanism of action of A2B530.

Lakshmi Nayak, MD, discusses the treatment landscape for patients with primary central nervous system lymphoma and how tirabrutinib may serve as an option for those with relapsed/refractory disease.

Two-year follow-up data from the RELATIVITY-047 trial showed a continued benefit for patients with previously untreated, unresectable, or metastatic melanoma receiving nivolumab plus relatlimab vs nivolumab monotherapy supporting the use of the combination.

Treatment with avutometinib plus defactinib elicited high responses among patients with recurrent low grade serous ovarian cancer compared with avutometinib monotherapy, supporting the use of the combination in this patient population regardless of KRAS status, according to data from the RAMP 201 trial.

Longer follow-up data from the phase 2 ELAINE-2 study demonstrated that treatment with lasofoxifene and abemaciclib resulted in clinically meaningful antitumor activity as well as continued tolerability with no new safety signals for patients with estrogen receptor-positive HER2-negative ESR1-mutated breast cancer who previously received CDK4/6 inhibitors.

Findings from a subgroup analysis of the phase 3 EMERALD trial presented during the 2023 ASCO Annual Meeting demonstrated elacestrant elicited prolonged progression-free survival compared with standard-of-care therapy for patients with estrogen receptor-positive, HER2-negative non-detected ESR1 mutated breast cancer who experienced disease progression within 6 months of CDK4/6 inhibitor treatment plus endocrine therapy.

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies.

Ilyas Sahin, MD, details the preclinical findings from the study and highlighted how these data could help inform future studies for the treatment of patients with MDM2-overexpressing solid tumors.

Amanda Bloomer, PhD, highlights the growing need for more research for this growing patient population and the age-specific findings that were seen in the ColoCare trial.

Nusayba Bagegni, MD, details ongoing research and possibilities for the treatment landscape in the future, which includes investigating escalating approaches through more research in clinical trials.

Sacituzumab govitecan-hziy produced comparable efficacy outcomes for patients with metastatic triple-negative breast cancer who had a higher incidence of grade 2 or 3 diarrhea and neutropenia vs patients in the overall population, according to a post hoc analysis of the phase 3 ASCENT trial presented at the 2023 ESMO Breast Cancer Annual Congress.

Adjuvant abemaciclib with endocrine therapy led to a tolerable safety profile in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer,

Treatment with adjuvant anastrozole over a 10-year period remained tolerable and increased disease-free survival rates in postmenopausal women with hormone receptor–positive breast cancer, according to data from the phase 3 AERAS trial.

Abhinav Deol, MD, gives insight on CAR T-cell therapy’s future role in the treatment landscape for multiple myeloma and what needs to be done to push the needle forward.

Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.

Treatment with adagrasib monotherapy led to clinically meaningful activity and a manageable safety profile in patients with KRAS G12C–mutated solid tumors.

Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/

Sarah B. Gitto, PhD, discusses the process of investigating the B7-H4 as a viable target for drug development in treatment-resistant ovarian cancer.

Matthew H. Taylor, MD, discusses findings from a phase 1 study of IO-108 in advanced solid tumors, which was presented during the 2023 AACR Annual Meeting.

Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.

To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.